Autopsy report · NCT06331559

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

“Company development strategy change”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 13 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.

Sponsor type

Industry

Conditions

Advanced Solid Tumors

Interventions

SIM0501 Tablets; SIM0501 Tablets; SIM0501 in combination with olaparib; SIM0501 in combination with olaparib

Participants

13

Sites

1

Countries

China

Trials that died the same way

• A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus
  “Company development strategy adjustment” (92% match in meaning)
• A Clinical Investigation to Assess the Effectiveness of Benzocaine Condoms in Healthy Adult Men
  “Change of the product development strategy” (83% match in meaning)
• Evaluate the Efficacy and Safety of Amnion Membrane Disc Allograft vs Standard of Care in Participants With Dry Eye Disease
  “Change in company strategy.” (82% match in meaning)
• IBI397 or Combination Therapies in Patients With Advanced Malignancies
  “Due to the company's development strategy adjustment” (78% match in meaning)
• ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
  “Business strategy change” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.